Highly galactosylated anti-TNF-α antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10174110-B2
Application number	US-201414767117-A
Country	US
Kind code	B2
Filing date	Feb 13, 2014
Priority date	Feb 13, 2013
Publication date	Jan 8, 2019
Grant date	Jan 8, 2019

Abstract

In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

First claim

What is claimed is:

1. A composition, comprising:
a population of antibodies,
wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal;
wherein the level of galactosylation of the antibodies in the population of antibodies comprises at least 5% mono-galactosylated N-glycans or at least 10% bi-galactosylated N-glycans;
wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and
wherein the antibodies in the population of antibodies comprise a heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2.

2. The composition of claim 1 , wherein at least 25% of the antibodies in the population comprise mono-galactosylated N-glycans and at least 35% of the antibodies in the population comprise bi-galactosylated N-glycans.

3. The composition of any one of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 40%.

4. The composition of claim 1 wherein the level of fucosylation of the antibodies in the population is 30.4%-78.2%.

5. The composition of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 50%.

6. The composition of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 60%.

7. The composition of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 70%.

8. The composition of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 80%.

9. The composition of claim 1 , wherein the level of fucosylation of the antibodies in the population is at least 90%.

10. The composition of any one of claim 1 , wherein the ratio of the level of galactosylation of the antibodies in the population to the level of fucosylation of the antibodies in the population is between 1.0 and 1.4.

11. The composition of any one of claim 1 , wherein the population of antibodies has an increased level of complement dependent cytotoxicity (CDC) activity when compared to a population of antibodies not produced in mammary gland epithelial cells.

12. The composition of any one of claim 1 , wherein the population of antibodies has an increased level of antibody-dependent cellular cytotoxicity (ADCC) activity when compared to a population of antibodies not produced in mammary gland epithelial cells.

13. The composition of claim 1 , wherein the transgenic non-human mammal is a goat, sheep, camel, cow, pig, rabbit, rat, mouse or llama.

14. The composition of claim 13 , wherein the transgenic non-human mammal is a goat.

15. A composition, comprising:
a population of antibodies,
wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal;
wherein at least 30% of the antibodies in the population of antibodies contain at least one oligomannose;
wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and
wherein the antibodies in the population of antibodies comprise a heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2.

16. The composition of claim 15 , wherein the antibodies in the population of antibodies exhibit a high mannose glycosylation pattern.

17. The composition of claim 16 , wherein at least one chain of the antibodies in the population of antibodies contains an oligomannose and is non-fucosylated.

18. The composition of claim 15 , wherein the major carbohydrate of the antibodies in the population of antibodies is non-fucosylated.

19. The composition of claim 15 , wherein the transgenic non-human mammal is a goat, sheep, camel, cow, pig, rabbit, rat, mouse or llama.

20. The composition of claim 19 , wherein the transgenic non-human mammal is a goat.

Assignees

• Lab Francais Du Fractionnement

Inventors

• Meade Harry M
• Chen Li-How

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title